Advertisement


Julien Taïeb, MD, PhD, on Colorectal Cancer: Recent Findings on Avelumab vs Standard Second-Line Chemotherapy

ESMO Congress 2022

Advertisement

Julien Taïeb, MD, PhD, of Paris Descartes University, discusses phase II results from the SAMCO-PRODIGE 54 trial, which shows the efficacy and safety of avelumab in the second-line treatment of patients with deficient DNA mismatch–repair microsatellite-instability metastatic colorectal cancer. According to Dr. Taïeb, the study indirectly suggests this population should be treated as soon as possible with an immune checkpoint inhibitor (Abstract LBA23).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Today we are going to talk about the SAMCO-PRODIGE 54 trial, which is a randomized phase two study dedicated to MSI high metastatic colorectal cancer patients that were treated with an PD-L1 called avelumab or a standout second line therapy. All patients have received only one previous line of treatment and we know that immune checkpoint inhibitors are efficient in the SSI high population in first line. However, there is only one randomized data to date and this is the second one dedicated to second line. So altogether 132 patients were recruited, have treated with avelumab have treated with a standard second-line chemotherapy, plus targeted agent, adapted to their rest status as usual. The primary endpoint of the trial was PFS and the patients were stratified for age ... mutation and number of stats. What we have seen in the result is that the primary endpoint is rich PFS is better in patients treated with the immunotherapy than the one treated with chemotherapy with a targeted agent. And what happened is that the curves are crossing several time, so it doesn't allow us to think with medians and as a ratio as usually, but we had to use the Q and chin test that is adapted when the shape of the curves is this way. What we can see also is that some patients are immediately resisting to immunotherapy. Some others are resisting within one year, as it was the case in the keynote 177 first line study, and that when the patients are controlled for several months, they are controlled for a very long period of time with approximately 25 to 30% of the patient controlled for more than two years. In this second line setting where generally overall survival are around one year or less. Concerning tolerability, what we have seen is that avelumab is better tolerated than chemotherapy with have less grade three four toxicities, 30% instead of 50% globally. So it validates the use of an NTP DL-1 or PD-L1 in second line treatment for MSI high colon cancer. However, the primary and secondary resistance occurring during the first care being more important in this trial than in the first line trial. We can say by cross study comparison, but that probably the best. The sooner is the better, and we have to treat this patient as soon as possible. Altogether this is a positive trial that will help us to find a treatment and have scientific data if we see a patient MSI High that has not been previously treated with immunotherapy in second line.

Related Videos

Skin Cancer

John B.A.G. Haanen, MD, PhD, on Melanoma: Phase III Data on Treatment With Tumor-Infiltrating Lymphocytes vs Ipilimumab

John B.A.G. Haanen, MD, PhD, of The Netherlands Cancer Institute, discusses recent phase III findings, which show that tumor-infiltrating lymphocytes (TILs) improve progression-free survival compared with ipilimumab by 50% in patients with advanced melanoma after not responding to anti–PD-1 treatment. Around 50% of TIL-treated patients had a response, and 20% had a complete response (Abstract LBA3).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Recent Phase III Data on Cabozantinib, Nivolumab, and Ipilimumab From the COSMIC-313 Trial

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss phase III findings showing that cabozantinib in combination with nivolumab and ipilimumab reduced the risk of disease progression or death compared with the combination of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma of IMDC (the International Metastatic RCC Database Consortium) intermediate or poor risk. However, the combination of cabozantinib, nivolumab, and ipilimumab vs nivolumab plus ipilimumab did not demonstrate an overall survival benefit to patients (Abstract LBA8).

Skin Cancer
Immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).

Pancreatic Cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).

Advertisement

Advertisement




Advertisement